Navigation Links
Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
Date:9/9/2009

DURHAM, N.C., Sept. 9 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that the company's proxy, which is being mailed today, asks shareholders to approve a 1-for-15 reverse stock split at the annual meeting on Oct. 19, 2009.

"At last years' general annual meeting we explained the problems of being listed over the counter on the bulletin board and we promised to seek a listing change as soon as we can qualify," said Chris Stern, company chairman and CEO. "We are working toward meeting the listing standards of a major exchange. In that regard we are proposing a reverse split of our outstanding common stock in an effort to meet the minimum stock price qualification requirement of a major stock exchange."

At the meeting, shareholders also will vote on the election of six directors. The current directors have been nominated by the Board for re-election.

The proxy is being mailed today to shareholders of record on Sept. 4, 2009. A copy of the proxy is available on the Investor Relations page of the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
2. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
3. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
4. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
5. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
6. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
9. Oxygen Biotherapeutics, Inc. Expands Board of Directors
10. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
11. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama's BRAIN (Brain Research through ... to revolutionize our understanding of the human mind ...
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/2/2014)... India , October 2, 2014 ... showcased its biometrics capabilities at the prestigious Annual Conference ... in Las Vegas , where they ... presented on varied topics like ,data analytics to support ... / registry studies, and ,benefits of working together as ...
(Date:10/1/2014)... Oct. 1, 2014  Discovery Laboratories, Inc. (Nasdaq: ... awarded a Phase II Small Business Innovation Research ... from the National Institute of Allergy and Infectious ... (NIH) to support the development of the Company,s ... countermeasure to mitigate acute and chronic/late-phase radiation-induced lung ...
Breaking Biology Technology:NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... , PHILADELPHIA, Sept. 16 BioNanomatrix, Inc., a ... and personalized medicine, today announced that Dr. Charles Lee and ... Dr. Lee is a pioneer in the field of ... Medical School and the Broad Institute. Dr. Barker, the ...
... , , , ... Pervasis Therapeutics, Inc. today announced that it completed the ... financing. The proceeds will be used primarily to support ... biologically active therapy designed to reestablish healthy vasculature following ...
... DENVER, Colorado and JERUSALEM, September 16 ... Venture announced today,that Children,s Hospital is enrolling patients for ... series of cord blood transplant sites,worldwide, five of which ... Spain, Italy, Hungary and Israel. The trial is researching ...
Cached Biology Technology:BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 2Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 3Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 4Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
(Date:9/29/2014)... study confirms that the exposure to tar tended to ... regular cigarettes. Similarly, exposure to nicotine tended to ... type of cigarette in several countries around the world. ... toxic chemicals in the smoke of these cigarettes are ... levels of chemicals in the smoke are not necessarily ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Slim cigarette smokers not exposed to more harmful chemicals 2
... University of Exeter has highlighted the problems of ... Published online in the journal Biological Conservation, the ... carnivores that are released into their natural habitats. ... survives in the wild, with most deaths related ...
... NEW YORK, January 20, 2008A landmark genetic study has ... or lupus, a debilitating autoimmune disease that affects an ... the joints, kidneys, heart, lungs, brain and blood and ... Women are nine times more likely than men to ...
... the Tenovus Centre for Cancer Research at Cardiff University ... could help save the lives of women who become ... While drugs such as tamoxifen have been a huge ... of sufferers the drugs either fail to work, or ...
Cached Biology News:Captive carnivores not up to wild living 2Steps toward Stopping Autoimmune Disease 2Further breakthroughs for breast cancer patients 2